RecruitingPhase 4NCT07025005

Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)

Studying Paraneoplastic neurologic syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Tanta University
Principal Investigator
Ashraf M Alaa, BSc of clinical pharmacy
clinical pharmacy departement - Faculty of Pharmacy - Tanta University
Intervention
Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg tablet(drug)
Enrollment
44 enrolled
Eligibility
18 years · All sexes
Timeline
20252026

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07025005 on ClinicalTrials.gov

Other trials for Paraneoplastic neurologic syndrome

Additional recruiting or active studies for the same condition.

See all trials for Paraneoplastic neurologic syndrome

← Back to all trials